1. A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. (7th June 2017) Authors: Lieu, Christopher H.; Hidalgo, Manuel; Berlin, Jordan D.; Ko, Andrew H.; Cervantes, Andres; LoRusso, Patricia; Gerber, David E.; Eder, J. Paul; Eckhardt, S. Gail; Kapp, Amy V.; Tsuhako, Amy; McCall, Bruce; Pirzkall, Andrea; Uyei, Anne; Tabernero, Josep Journal: Oncologist Issue: Volume 22:Number 9(2017) Page Start: 1024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. (September 2017) Authors: Lieu, Christopher H.; Hidalgo, Manuel; Berlin, Jordan D.; Ko, Andrew H.; Cervantes, Andres; LoRusso, Patricia; Gerber, David E.; Eder, J. Paul; Eckhardt, S. Gail; Kapp, Amy V.; Tsuhako, Amy; McCall, Bruce; Pirzkall, Andrea; Uyei, Anne; Tabernero, Josep Journal: Oncologist Issue: Volume 22:Number 9(2017) Page Start: 1024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 6 (June 2019) Authors: Eng, Cathy; Kim, Tae Won; Bendell, Johanna; Argilés, Guillem; Tebbutt, Niall C; Di Bartolomeo, Maria; Falcone, Alfredo; Fakih, Marwan; Kozloff, Mark; Segal, Neil H; Sobrero, Alberto; Yan, Yibing; Chang, Ilsung; Uyei, Anne; Roberts, Louise; Ciardiello, Fortunato Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10240 (13th June 2020) Authors: Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A; Ascierto, P... Journal: Lancet Issue: Volume 395:Issue 10240(2020) Page Start: 1835 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗